Department of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
Arch Pathol Lab Med. 2013 Aug;137(8):1117-28. doi: 10.5858/arpa.2012-0326-RA.
Myofibroblastic proliferations of the urinary bladder, which share some similarities with nodular fasciitis, were first reported in 1980. Since then, they have had several designations, the most frequently used being inflammatory myofibroblastic tumor. Based on both histopathologic and prognostic grounds, some authors prefer the term pseudosarcomatous myofibroblastic proliferation, at least for some of the proliferations. These same scientists also assimilate the so-called postoperative spindle cell nodules with the pseudosarcomatous myofibroblastic proliferations. Little is known about these low-grade myofibroblastic proliferations.
To review the literature about low-grade myofibroblastic proliferations occurring in the urinary bladder.
Textbooks and literature review. We obtained most of the clinicopathologic peculiarities from a patient population composed of the most-relevant, previously reported cases.
The low-grade myofibroblastic proliferations of the urinary bladder are rare lesions affecting males more often than they do females. The most-common signs and symptoms are hematuria and dysuria. Histopathologically, they are spindle cell proliferations in a loose myxoid stroma, even though compact proliferations or hypocellular fibrous patterns can be found. Immunohistochemistry is quite nonspecific, except for ALK-1 positivity (20%-89%). Fluorescence in situ hybridization has demonstrated clonal genetic aberrations involving the ALK gene in 50% to 60% of cases. After surgery, only 6% of patients experience local recurrence, without metastases or deaths from the disease. Malignant transformation has been reported exceptionally. These myofibroblastic proliferations are probably part of a continuum with, at one end, benign pseudosarcomatous proliferations and, at the opposite end, more-aggressive lesions. Because of the frequently indolent clinical course, aggressive treatment would be unjustified.
膀胱的肌纤维母细胞增生与结节性筋膜炎有一些相似之处,于 1980 年首次报道。从那时起,它们有了几个名称,最常用的是炎性肌纤维母细胞瘤。基于组织病理学和预后的原因,一些作者更喜欢使用“假肉瘤性肌纤维母细胞增生”这一术语,至少对于一些增生而言是如此。这些同样的科学家还将所谓的术后梭形细胞结节与假肉瘤性肌纤维母细胞增生同化。人们对这些低度肌纤维母细胞增生知之甚少。
复习膀胱低度肌纤维母细胞增生的文献。
教科书和文献复习。我们从由大多数相关的、以前报道过的病例组成的患者群体中获得了大部分临床病理特征。
膀胱低度肌纤维母细胞增生是一种罕见的病变,男性比女性更常受累。最常见的症状和体征是血尿和排尿困难。组织病理学上,它们是疏松黏液样基质中的梭形细胞增生,尽管也可以发现致密性增生或低细胞纤维模式。免疫组织化学表现相当非特异性,除了 ALK-1 阳性(20%-89%)。荧光原位杂交显示,50%-60%的病例存在涉及 ALK 基因的克隆遗传异常。手术后,只有 6%的患者出现局部复发,无疾病转移或死亡。极少数情况下有恶性转化的报道。这些肌纤维母细胞增生可能是良性假肉瘤性增生和更具侵袭性病变的连续体的一部分。由于其通常呈惰性的临床病程,过度治疗是不合理的。